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Introduction 
Psoriasis is a common cutaneous disease affecting 2 % of the population. However, 
there are global variations in incidence in that it is rare in Native Americans and 
commoner in Northern Europe. The disease is characterized by two main 
histological features namely epidermal hyperproliferation coupled with an inflam- 
matory infiltrate. Until about 15 years ago experimental dermatologists resear- 
ching the pathogenesis of psoriasis focused the majority of their attention on the 
hyperproliferative epidermal compartment and paid scant regard to the inflam- 
matory infiltrate. Indeed, if one had questioned dermatologists in the 1970s as 
to whether immunological mechanisms played an integral role in the pathogenesis 
of psoriasis, it is probable that the overwhelming majority would have answered 
negatively. As a result of pioneering work performed in Europe and as a conse- 
quence of the proven efficacy of the selective T cell immunosuppressant, 
cyclosporine, it is now established that psoriasis is indeed immunologically 
mediated. 
This article delineates the various immunological mechanisms believed to be 
involved in the psoriatic process, debates the relative impact of the contributions 
each pathway brings to the production of the psoriatic phenotype, and describes 
how newer immunoregulatory approaches to this disease have helped strengthen 
the immune-mediation hypothesis. 
Genetics 
The evidence that psoriasis is a genetically determined disease is considerable. 
Approximately one-third of affected individuals have at least one first-degree 
relative with psoriasis and epidemiological studies from Northern Europe have 
determined that relatives of psoriatics are three times more likely to suffer from 
Correspondence to: C. E. M. Griffiths 
442 C.E.M. Griffiths and J.J. Voorhees 
the disease than are comparable members of the general population [53, 65]. A 
concordance rate of approximately 70% for monozygotic twins and 15%-30% 
for dizygotes seems to indicate an autosomal dominant inheritance [19, 33, 65, 
101], although the comparatively low concordance rate in monozygotes implies 
that environmental factors play a key role in the expression of the psoriatic 
phenotype. Work by Hensler and Christophers [54] categorized psoriatics into 
two types dependent on age at onset of the disease. In the first type (type I), there 
is a strong association with the class I MHC antigen HLA-Cw6 which occurs in 
85 % of individuals in this group. In the second group (type II) characterized by 
late age of onset, (60 years old on average) there is a low association with HLA- 
Cw6. HLA-Cw6 is in linkage disequilibrium with HLA-B13, Bwl7, and Bw37 
and these three antigens are also more prevalent in psoriatics [89, 101, 103]. The 
association of psoriasis with HLA antigens provides incidental evidence for the 
importance of an autoimmune-based concept, particularly the high prevalence of 
HLA-DR7 and the strong correlation with HLA-B27 in those subjects who have 
psoriatic sacro-ileitis [3, 40, 106]. Ozawa et al. [83] was unable to find a strong 
relationship between HLA-Cw6 and psoriasis but did observe that in control, non- 
psoriatic subjects a restriction fragment length polymorphism (RFLP) in the 
1-alpha-2 domain of Cw6 was lacking, thereby implying that its presence provided 
an increased suseptibility to psoriasis. 
The increased incidence of the class I MHC molecule HLA-Cw6 or lack of 
an important RFLP for Cw6 in normal subjects would indicate an importance of 
CD8 § T cells in psoriasis as these "suppressor" cells only bind and activate in 
the context of MHC class I. On these grounds it is possible that failure of CD8 
suppression of CD4-driven activation may account for the persistence of psoriatic 
plaques [48]. Unfortunately, it is unlikely to be as simple as this postulation and 
most probably the role of class II MHC alleles, such as DR7, in recognition of 
specific antigens is as necessary as class I MHC restriction. Thus, inheritance 
is probably not one of a single "psoriasis gene" but likely is multifactorial with 
environmental factors such as infection holding a controlling interest in phenotypic 
expression of this genetic predisposition. 
The role of T lymphocytes 
Evidence exists for an impaired cell-mediated immunity in psoriasis [38]. Delayed 
hypersensitivity to standard prick-test antigens and streptococcal antigen is reduced 
in psoriatics, and intradermal antigen testing to purified protein derivative (PPD) 
is characterized by slow resolution of the reaction [30, 60, 70]. In vitro there is 
an inability of T cells from psoriatics to proliferate in response to concanavalin 
A [50]. Perhaps the most striking demonstration of an abnormality (perhaps 
genetic) in cellular T lymphocyte function in psoriatics are the reports of a cure 
of the disease following allogeneic bone marrow transplant [27]. This thesis is 
buttressed by the converse finding of transmission of psoriasis with allogeneic 
bone marrow transplant [36]. 
It was only with the advent of monoclonal antibodies that a rigorous investiga- 
tion of the components of the dermal and epidermal inflammatory infiltrate in 
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psoriatic lesions could be performed. Until then it was known only that the T 
lymphocyte was a part of the infiltrate but subdivision into CD4, CD8, natural 
killer cells etc, could not be performed. In 1978 Bjerke et al. [15] demonstrated 
that the majority of the infiltrate was comprised of T cells of which CD4 § cells 
formed the major part. Not until the work of Baker and colleagues [4, 100] was 
it apparent that the actual ratio ofCD4:  CD8 cells was important to both the genesis 
and resolution of a psoriatic plaque and that activation or HLA-DR expression 
of these subsets was also critical. 
In normal skin there is a small yet significant epidermal traffic of T cells and 
these are mainly of the CD4 § subset [18]. In active, evolving psoriasis of the 
guttate form there is an intraepidermal influx of activated DR § CD4 § T cells, 
and the ratio of CD4+ :CD8 § T cells is greater than that observed in peripheral 
blood of the same individuals [4, 100]. Indeed, the absolute numbers of total and 
CD4 § T lymphocytes in the blood of psoriatics is lower than in normal subjects 
[5]. These numbers correlate with disease extent and may be a result of cutaneous 
sequestration. Spontaneous resolution of guttate psoriasis lesions is predated by 
an intraepidermal influx of DR § CD8 § T cells coinciding with a decrease in 
DR § CD4 § cells [4, 100]. The same phenomenon is observed during treatment 
of psoriatic plaques with psoralen ultraviolet A (PUVA) [10]. Indirect evidence 
for a role for activated CD4 § T lymphocytes in psoriasis accrues from several 
sources. Psoriatic epidermal keratinocytes exhibit patchy expression of HLA-DR 
[4, 8], and although the extent of this keratinocyte HLA-DR expression is 
debatable, its presence probably indicates local production of gamma interferon 
(IFN-3,) [4, 8, 14, 41]. IFN-3~ is produced solely by activated CD4 + T cells and 
is the only cytokine capable of inducing the expression of HLA-DR [46, 78]. Other 
indirect evidence for the presence of activated CD4 § T cells is detection of both 
IFN-3, mRNA and protein in psoriatic plaques [14] and keratinocyte expression 
of IFN-7-inducible protein (IP-10) [42] and ICAM-1 [46]. Activation of CD4 § 
T cells results in expression of the interleukin (IL)-2 receptor (IL-2R) and although 
there are no reports of IL-2 in psoriatic plaques there are increased levels of IL-2R 
in suction blister fluid [95]. 
Support for the importance of T lymphocytes in the induction and maintenance 
of psoriatic plaques comes from evidence derived from the efficacy in this disease 
of the relatively T cell-specific immunosuppressant cyclosporine. This evidence 
will be presented later in the chapter. 
In the regrettable absence of a good animal model for psoriasis, researchers 
must utilize early stages of the disease itself for investigation. The Koebner 
phenomenon which is the ability of traumatized, uninvolved psoriatic skin to 
develop psoriasis is a useful model for the early events in the genesis of a psoriatic 
plaque. Koebnerization occurs in only 25 % of psoriatics at any one time and is 
entirely dependent on disease activity [32]. In subjects who are Koebner positive 
there is evidence that the epidermal CD4:CD8 ratio in uninvolved skin is 
significantly higher than in those who are Koebner negative [7]. The increase in 
T cell subset ratio is mainly contributed to by a decrease in CD8 § cells implying 
a removal of suppression and subsequent triggering of the response threshold. 
Although difficult to place in the context of the pathogenesis of psoriasis, it 
is certain that humoral factors play a role. Stankler [92] made the salient observa- 
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tion that serum from patients recovering from active psoriasis had an inhibitory 
effect on the Koebner reaction and a healing action when injected into active 
lesions. This was contrasted to the non-inhibitory effect of serum from subjects 
with ongoing, active psoriasis. 
The role of antigen-presenting cells 
Psoriatic epidermis contains increased numbers of CD 1 -D R + cells, whereas 
there is debate as to the number of CDI+DR § Langerhans cells, with views 
varying from no difference from that found in normal or uninvolved psoriatic skin 
to increased or decreased numbers as compared to normal. The ability of psoriatic 
epidermal cell suspensions to stimulate autologous T cell activation and prolifera- 
tion seems to be dependent on this CD1-DR § subset [2]. Differing views exist 
as to the nature of these C D 1 - D R  § cells. They may be a heterogeneous group 
of  macrophages and antigen-presenting cells [2] or, alternatively, immature 
Langerhans cells [6, 9]. Certainly the C D 1 - D R  + population is not specific for 
psoriasis but is found in other inflammatory dermatoses [9]. Alternatively, the 
CD1 surface antigen may be lost on activation of the Langerhans cell or in the 
presence of IFN-'y and the C D 1 - D R  § group may represent activation and 
heightened antigen-processing capacity of resident Langerhans cells. 
The dermis, although admittedly a more difficult cutaneous compartment to 
study than epidermis, has received little attention as far as antigen-processing 
capabilities are concerned. Dermal Langerhans cells are increased in psoriatic 
relative to normal skin and are found clustered around the vessels of the dermal 
papillae [17]. This observation has been made in other inflammatory dermatoses 
such as allergic contact dermatitis and cutaneous T cell lymphoma [11, 68]. A 
recently described putative dermal antigen-presenting cell which resides in the 
upper papillary dermis and perivascular locale is the Factor XIIIA-positive dermal 
dendrocyte [52]. In psoriasis, the dermal dendrocytes are increased in number 
and appear to be activated by virtue of increased dendricity and DR positivity 
[20, 79]. These observations indicate a propensity for heightened dermal process- 
ing of antigen and possibly cytokine production in psoriasis. 
The role of cytokines 
Cytokines are small, cell-derived polypeptides which serve as intercellular chemi- 
cal messengers. Initially believed to be secreted solely by lymphocytes and 
monocytes it is now recognized that virtually all cell types found within the skin 
are capable of producing these molecules. A most significant advance in our 
understanding of  the cutaneous cytokine network came with the recognition that 
the keratinocyte is not merely an inactive, protective coating to the skin but is 
an active component of the skin immune system imbued with cytokine-secreting 
capacity [13]. The availability of  sensitive assays, monoclonal antibodies and 
molecular techniques such as the polymerase chain reaction (PCR) have facilitated 
our ability to detect cytokines within the skin. Unfortunately, with the relentless 
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discovery of new cytokines comes the heightened complexity of understanding 
how they interact with one another to maintain a homeostatic cutaneous milieu 
or initiate and perpetuate a disease process such as psoriasis. 
IL-1 with its ability to induce expression of endothelial adhesion molecules 
ICAM-1, ELAM-1, and VCAM-1 [47] and its capabilities of mononuclear cell 
chemotaxis and induction of keratinocyte proliferation would appear a good 
candidate for elevation in psoriasis [3]. Somewhat unexpectedly, activity of this 
interleukin in psoriasis is reduced as compared with normal or uninvolved psoriatic 
skin [23]. The observed reduction in IL-1 activity is a result of several com- 
pounding factors, namely reduced levels of IL-lo~, the presence of a functionless 
form of IL-/3 (although protein levels are increased) and the appearance of an IL-1 
inhibitor in psoriasis [23, 51]. The reduced levels of IL-I activity in chronic plaque 
psoriasis may be attributable to consumption of IL-1 during evolution of the lesion 
and thus research directed at early, evolving psoriatic lesions could reveal 
increased IL-1 activity at this critical time. 
IL-2 is produced by activated CD4 § T cells and the presence of soluble 
IL-2R is indicative of activation. It is surprising that detection of this cytokine 
has not been reported in psoriatic skin. Suction blister assays and immunoperox- 
idase studies of cryostat sections have demonstrated increased levels of IL-2R in 
involved but not uninvolved psoriatic skin implying prior T cell activation [95]. 
Increased levels of soluble IL-2R have been detected in both atopic dermatitis and 
psoriasis [58, 59]. The report by Lee et al. [62] that intravenous IL-2 used for 
the treatment of carcinoma produced marked flaring of incidental psoriasis in two 
subjects indicates that IL-2 may be of prime importance in the initiation of a 
psoriatic response. As with IL-1 the absence of IL-2 in chronic, stable plaques 
of psoriasis may warrant investigation of the evolving lesion with its concomitant 
influx of activated CD4 § T cells. 
IL-6 is produced by fibroblasts, keratinocytes, T cells and macrophages and 
is known to be capable of stimulating keratinocyte proliferation [48]. Increased 
levels of IL-6 mRNA and protein have been found in both psoriatic plaques [48] 
and sera and levels of IL-6 protein are increased in psoriatic keratinocytes in vitro 
[76]. 
IL-8, previously known as neutrophil-activating peptide or neutrophil- 
activating factor, was first described as a chemotactic agent for neutrophils but 
is now recognized as a particularly potent T lymphocyte chemoattractant [61]. 
IL-8 is produced by keratinocytes, fibroblasts, and lymphocytes and is capable 
of inducing keratinocyte proliferation in vitro [88]. With this psorigenic capacity 
it is not surprising that IL-8 protein and mRNA have been observed in psoriatic 
plaques [21, 37, 81] and it is possible that this cytokine plays an important 
pathogenic role. 
Tumor necrosis factor-alpha (TNF-o0 has been demonstrated immunohisto- 
logically in the dermis of psoriatic plaques and is primarily localized to dermal 
dendrocytes with limited expression by Langerhans cells [81]. PCR of isolated 
psoriatic epidermis, however, did not demonstrate TNF-c~ mRNA [14], although 
TNF-c~ protein has been variously reported as being either elevated or decreased 
in psoriatic serum [39, 73]. Indirect evidence for the presence of TNF-ot is the 
presence of TNF-o~-inducible molecules such as transforming growth factor-o~ 
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(TGF-oL) [28, 99] and IL-8 as well as endothelial expression oflCAM-1, VCAM-1 
and ELAM-1 and keratinocyte expression of ICAM-1; TNF-o~ is the only cytokine 
known to induce this pattern of adhesion molecule expression [47]. Furthermore, 
angiogenesis which is an important component of psoriatic plaques, has been 
shown to be inducible by macrophage-derived TNF-ot [63]. Epidermal changes 
are known to precede angiogenesis in advancing psoriatic plaques [84] and epider- 
mal-derived angiogenic factors such as TNF-ot may be responsible for this observa- 
tion [67, 105]. Nickoloff [78] has proposed an elaborate thesis based upon the 
presence of TNF-o~ in psoriasis and has proposed this cytokine as the orchestrator 
of the disease process. However, systemically administered TNF-o~ is reported 
to clear psoriasis [24, 96] and injection of this cytokine into mouse tail inhibits 
keratinocyte proliferation [74]. It may be that supraphysiological levels of TNF-o~ 
overload and consequently down-regulate its receptors leading to a paradoxical 
inhibitory effect and consequent disease resolution. 
Of all the cytokines measured so far in psoriasis, the candidate most likely 
to be central to the T cell-mediated paradigm for this disease is IFN-'y. IFN-'y 
is produced solely by activated CD4 § T cells and indirect evidence for its 
existence in psoriatic plaques is keratinocyte expression of ICAM-1, HLA-DR, 
and IP-10 [41, 42, 44, 90]. PCR examination of epidermal sheets derived from 
psoriatic lesions reveals the presence of mRNA for IFN-'y, whereas this cytokine 
is absent in normal skin [14]. IFN-3, protein has been demonstrated in fluid from 
suction blisters raised on involved but not uninvolved psoriatic skin [16, 95] and 
is elevated in serum from psoriatic patients [39]. By comparison with normal 
keratinocytes, psoriatic keratinocytes are less sensitive to the growth inhibitory 
effects of IFN-3/in culture and are less disposed to expression of HLA-DR and 
ICAM-1 [8, 80]. These observations indicate that psoriatic keratinocytes are 
hyporesponsive to IFN-3,. During the course of treating psoriatic arthritis with 
subcutaneous injections of IFN-3/, it was observed in 10 of 42 patients that punc- 
tate, psoriatic foci were induced at the sites of injection of IFN-3, but not at the 
sites of vehicle injection [34]. Furthermore, injection of IFN--y in normal subjects 
did not evoke this response. This observation is circumstantial evidence for an 
integral role for IFN-q/ in psoriasis. 
TGF-o~ is a potent inducer of keratinocyte hyperproliferation and is overex- 
pressed in psoriatic plaques at both the mRNA and protein levels [28, 99]. The 
receptor for TGF-o~ (TGF-o~ - R/EGF-R) is increased in psoriatic epidermis [75]. 
Keratinocyte production of TGF-o~ can be induced by IFN--y [80] and IL-6 in vitro. 
It appears that increases in TGF-c~ and subsequent epidermal hyperproliferation 
do not occur at the expense of a decrease in the growth-inhibiting cytokine TGF- 
/31, as levels of this molecule appear to be the same in normal and psoriatic skin 
[28]. 
The role of  an adhesion molecules 
The discovery of adhesion molecules pertinent to cutaneous biology came with 
the observation that ICAM-1 expression could be induced on keratinocytes and 
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endothelial cells by TNF-a and IFN-3, [25]. Since then additional endothelial adhe- 
sion molecules have been described and there is little doubt that their interactions 
with mononuclear cells are pivotal to our understanding of cutaneous trafficking 
and inflammation. In normal, uninflamed skin, ICAM-1 is the sole adhesion 
molecule expressed and then only on endothelium [46, 90]. The expression of 
ICAM-1 by keratinocytes is indicative of the presence of TNF-ot and/or IFN-3,, 
although protein kinase C agonists such as urushiol can directly induce keratincyte 
expression of ICAM-1 [44]. Endothelial expression of ICAM-1 can be up- 
regulated by TNF-e~, IFN-7, IL-1 and lipopolysaccharide. The two adhesion 
molecules peculiar to endothelium, ELAM-1 and VCAM-1, are only induced by 
IL-1 and TNF-o~ [78]. 
In psoriatic epidermis keratinocyte ICAM-1 is focally expressed, particularly 
in the region immediately overlying the dermal papillae and ICAM-l-expressing 
keratinocytes are observed closely juxtaposed to infiltrating LFA-l-expressing 
lymphocytes [46]. ICAM-1, ELAM-1, and VCAM-1 are all expressed by psoriatic 
endothelium, thereby implying the presence of IL- 1 and/or TNF-o~ [49]. ELAM- 1 
binds neutrophils, monocytes and memory T cells. The receptor for ELAM-1 
expressed by a distinct skin-homing subset of memory T cells is the cutaneous 
lymphocyte-associated antigen (CLA) [85]. This observation coupled with the 
finding that ELAM-1 is preferentially expressed in skin and synovium [82] may 
be of considerable importance to the pathogenesis of inflammatory skin disease, 
especially pertinent in the case of psoriasis with its associated arthritis. 
New therapies as investigatory tools in psoriasis 
The ability of selective immunosuppressive agents to suppress the cutaneous 
manifestations of psoriasis has been salutory in strengthening belief in the immune- 
mediated hypothesis of this disease. Perhaps the one drug which has done most 
to further this hypothesis has been cyclosporine. In 1979, Mueller and Hermann 
[72] made a salient serendipitous observation during a study of the use of oral 
cyclosporine for arthritis. In this study four subjects happened to have psoriatic 
arthritis and their concomitant cutaneous plaques resolved rapidly after initiation 
of therapy. Subsequently, open and double-blind studies of cyclosporine in 
psoriasis have confirmed this observation [30, 43, 45]. What then is the 
significance of these observations to our understanding of the pathogenesis of 
psoriasis? 
Cyclosporine has a mechanism of action directed mainly at the CD4 § T 
lymphocyte and is known to inhibit its production of IL-2 and IFN-3/ [22, 29, 
57]. Inhibition occurs as a result of cyclosporine complexing with its receptor, 
cyclophilin, which is a member of the peptidyl-prolyl cis-trans isomerase group 
of enzymes which are important in protein re-folding [94]. The cyclosporine/ 
cyclophilin complex subsequently inhibits a calcium-activated protein, calcineurin 
phosphatase, and blocks translocation from the cytoplasm to the nucleus of a 
component of nuclear factor of activated T cells (NFAT) which ultimately leads 
to inhibition of T cell activation [22, 31, 64]. Cyclosporine has no direct 
antiproliferative effect on keratinocytes except under non-physiological, low 
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calcium, serum-free conditions where the concentration of cyclosporine exceeds 
that measured in skin during systemic treatment of psoriasis [35]. Lamellar 
ichthyosis is an autosomal recessive disease chracterized by epidermal hyper- 
proliferation which occurs in the absence of any appreciable lymphocytic infiltrate. 
Treatment of this condition with cyclosporine has been unsuccessful [55], an obser- 
vation which provides strong but circumstantial evidence that the hyperpro- 
liferative keratinocyte is not cyclosporine's primary target. 
When psoriasis is treated with systemically administered cyclosporine a large 
reduction in CD4 § and CD8 § T cells occurs within the plaques but only a small 
decrease in the DR§ + T cell subset [6]. This observation implies that, 
although activated DR+CD4 § cells are still present, they are in effect paralyzed 
and unable to produce cytokines capable of perpetuating the psoriatic process. 
The failure of topically applied cyclosporine in the treatment of psoriasis [43] 
necessitated intralesional studies of this drug in chronic plaque psoriasis, an 
approach which produces resolution of the injected plaques over a period of 4 
weeks. Sequential biopsies taken during those studies led to seminal observations 
concerning the role of CD4 § T cells. Prior to any clinical improvement, a reduc- 
tion occurs in numbers of intraepidermal DR+CD4 § T cells, however, imme- 
diate to this event there is a 67 % reduction in keratinocyte ICAM-1 expression 
implying inhibition of DR+CD4 § T cell-derived IFN-7 [43, 56]. It is postulated 
that a reduction in keratinocyte ICAM-1 expression would free LFA-1-expressing 
T cells from their apposition to keratinocytes and allow their return to the dermis 
and hence to recirculation. Other cytokines (such as IL-6) derived from T cells 
could also be inhibited by cyclosporine ultimately leading to resolution. FK506 
is a macrolide antibiotic, structurally unrelated to cyclosporine but with an ex- 
tremely similar mechanism of action and binding protein [98], which has been 
reported successful in the treatment of psoriasis [ 1 ]. The efficacy of this macrolide 
antibiotic further emphasizes the T cell-mediated nature of psoriasis particularly, 
as FK506 also has no direct effect on keratinocytes [91]. 
Newer, more specific therapies targeted at the T cell and the T cell receptor 
are being introduced into the treatment of autoimmune disease and both by design 
and by chance these have been used in psoriasis. Monoclonal antibodies targeted 
at the T cell, e. g., anti-CD3, are being used for the treatment of multiple sclerosis. 
One such patient also suffering from psoriasis was treated with anti-CD3 and a 
marked improvement in psoriasis was noted [102]. More specific antibodies 
directed against CD4, are also in use. To date, there are three reports totalling 
five patients which indicate that systemically administered anti-CD4 monoclonal 
antibodies will clear or markedly improve psoriasis [77, 86, 87]. As with all 
therapies for psoriasis, the disease relapses after cessation of treatment. 
Many all-encompassing theories have been proposed for the immunopatho- 
genesis of psoriasis and only time will dictate their accuracy [3, 12, 78]. For any 
theory to be viable, it should take into account the following points: inheritance, 
Koebner phenomenon, epidermal hyperproliferation, inflammation and angio- 
genesis. 
Antigen presentation to cutaneous T cells by Langerhans cells, dermal 
dendrocytes, and possibly keratinocytes most likely motivates the psoriatic process 
in genetically predisposed individuals. The most attractive candidates (on current 
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knowledge) for putative initiating antigens are members of the/3-hemolytic strep- 
tococcal family [97]. The propensity of streptococcal infection (particularly of the 
/3-hemolytic sub-type) to exacerbate chronic plaque psoriasis and initiate guttate 
psoriasis has been widely reported [97, 104]. Additionally, systemic antibiotics, 
e. g., penicillin, are known to prevent recurrence of the disease process. McFadden 
[69] has hypothesized that the observed reduction in delayed-type hypersensitivity 
to streptococcal antigen in psoriatics may serve as a protective mechanism against 
scarlet fever. The M protein of streptococci has the ability to behave as a superan- 
tigen, thereby activating T cells without class II MHC restriction. Molecular 
mimickry and cross reactivity between streptococcal protein and keratins may also 
account for perpetuation [71, 93]. Viral particles are also implicable as has been 
learnt from the exacerbation of psoriasis by AIDS most probably as a result of 
presentation of HIV antigens by Langerhans cells and dermal dendrocytes to T 
lymphocytes within the skin [26, 66]. Thus, in AIDS patients with psoriasis there 
is a somewhat paradoxical vigorous immune response taking place within the skin 
occurring in the face of systemic immunosuppression. 
Activation of Langerhans cells and dermal dendrocytes would initiate produc- 
tion of IL-1 and TNF-a both of which are capable of inducing ELAM-1, ICAM-1, 
and VCAM-1 on dermal capillary endothelium. TNF-ot can further induce TNF-~ 
production by keratinocytes in both autocrine and paracrine fashions and stimulate 
IL-8 production by keratinocytes. In addition, TNF-c~ and other epidermal-derived 
cytokines would stimulate angiogenesis. Endothelial adhesion molecule expres- 
sion, particularly ELAM-1, would allow binding of circulating T cells most 
probably of the memory, CLA-expressing subset. IL-8 and IL-1 derived both from 
keratinocytes and dermal dendrocytes may attract these adherent T cells away from 
the vascular wall and towards dermal antigen-presenting cells. Subsequent to this 
migration and antigen-processing, the T cells are activated. In all likelihood T 
cells could be activated at sites distal to the skin, such as lymph nodes and tonsils 
and then migrate to the skin in a fully primed state, thus obviating the need for 
cutaneous antigen presentation. Activation releases a cascade of cytokines 
including IFN-3, which in turn up-regulates ICAM-1 on keratinocytes allowing 
close T cell/keratinocyte binding and subsequent interactions. Once the amplifica- 
tion process has begun, further production of cytokines such as IL-6, IL-8, and 
TGF-a will promulgate epidermal hyperproliferation and overwhelming of the 
negative feedback imposed by CD8 § T cells. 
The Koebner phenomenon may be explicable by direct epidermal injury (which 
is necessary for this process) releasing keratinocyte-derived cytokines, such as 
IL-1 and TNF-a, capable of up-regulation of endothelial and keratinocyte adhesion 
molecules and initiation of T cell trafficking without recourse to antigen pre- 
sentation. 
The defect in psoriasis, which most likely is multifactorial, may reside in the 
keratinocyte, Langerhans cell or T cell. However, to explain the decreased 
sensitivity of psoriatic keratinocytes to IFN-3,, the enhanced antigen-presenting 
capacity of psoriatic Langerhans cells, the defects in cellular immunity and the 
"cure"  of psoriasis by allogeneic bone marrow transplant, it is possible that the 
genetic defects are expressed in multiple cell types and that no abnormality in 
a single cell type can account for all the features of psoriasis. 
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Conclusions 
The  pas t  decade  has borne  witness to t remendous  advances  in our  knowledge  o f  
the pa thogenes i s  o f  psor ias is  and the weight  of  ev idence  is now on the side o f  
the T cell  as be ing  an integral  media to r  o f  this process .  Advances  in molecu la r  
t echno logy  have enabled  di rec t  in vivo measuremen t  o f  cy tokines  and,  a l though 
no animal  mode l  exists  for  the study o f  psor ias is ,  the use o f  cyc lospor ine  has served 
as an exce l len t  inves t iga tory  tool.  The ut i l izat ion o f  therapeut ics  to study psor ia t ic  
mechan i sms  is an unusual  approach  in that one must  der ive  conclus ions  f rom disap-  
pea rance  o f  measurab le  factors such as cy tokines  and assume that these same 
factors  are  vi tal  to the ini t iat ion and maintenance  o f  a psor ia t ic  plaque.  S tudying  
d isease  evolu t ion  using the Koebner  phenomenon  or  re lapse fol lowing t rea tment  
would  supply  a more  accurate  pic ture  o f  ini t iat ing events.  Based on the immune  
hypothes is ,  therapeut ic  modal i t ies  which are now enter ing the arena include T 
cell  vacc ina t ion ,  par t i cu la r ly  i f  psor ias i s - spec i f ic  T cell  receptor  V f r e s t r i c t e d  
c lones  can be isola ted f rom psor ia t ic  plaques .  
The re  is l i t t le  doubt  that by the end o f  this century,  cutaneous b io logis ts  wil l  
have bui l t  substant ia l ly  on the immunolog ica l  foundat ion laid by the ear ly work  
out l ined  here.  Mos t  l ikely the genet ic  contr ibut ion(s)  to the manifes ta t ions  of  
psor ias i s  wil l  be more  fully e luc ida ted  and that  gene therapy will  car ry  more  than 
a futuris t ic  p romise .  At  least  for  the present  we be l ieve  that  such signif icant  
advances  have been  made  that the major i ty  o f  dermato logis t s  i f  quest ioned 
nowadays  as to whether  psor ias is  is an immuno log ica l ly -med ia t ed  disease  would  
answer  in the aff i rmat ive .  
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